GoodRx (GDRX) Q3 2024 Earnings Call Transcript
Welcome to the GoodRx third-quarter 2024 earnings call. As a reminder, today's conference call is being recorded. I would now ...
pharmaphorum6d
Can Novo Nordisk’s pipeline transform obesity treatment?
Novo Nordisk's Saxenda injectable drug is aimed at the obesity market The daily injectable drug has been priced at $1,000 a month, far higher than its rival oral treatments, Vivus' Qsymia ...